PT  - JOURNAL ARTICLE
AU  - Davor Bajic
AU  - Kerry A. Chester
AU  - Dario Neri
TI  - An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer
AID  - 10.1101/698563
DP  - 2019 Jan 01
TA  - bioRxiv
PG  - 698563
4099  - http://biorxiv.org/content/early/2019/07/17/698563.short
4100  - http://biorxiv.org/content/early/2019/07/17/698563.full
AB  - We have cloned and characterized a novel fusion protein (Sm3E-TNF), consisting of the monoclonal antibody Sm3E in single-chain Fv fragment format, fused to murine tumor necrosis factor. The protein, which was expressed in mammalian cells and purified as a non-covalent stable homotrimer, bound to the cognate carcinoembryonic antigen (CEA) and retained tumor necrosis factor activity. A quantitative biodistribution experiment, performed in immunocompetent mice with CT26 colon carcinomas transfected with human CEA, revealed that Sm3E-TNF was able to preferentially accumulate in the tumors with excellent selectivity (tumor:blood ratio = 56:1, twenty-four hours after intravenous administration). The fusion protein mediated a rapid hemorrhagic necrosis of a large portion of the tumor mass, but a rim survived and eventually regrew. Surprisingly, the combination of Sm3E-TNF with 5-fluorouracil led to a reduction of therapeutic activity, while a combination with oxaliplatin led to a prolonged stabilization, with complete tumor eradication in 40% of treated mice. These therapy results were confirmed in a second immunocompetent mouse model of colorectal cancer (CEA-transfected C51 tumors) and provide a rationale for the possible clinical use of oxaliplatin in combination with fully-human antibody-TNF fusions.